11-03-2025
Orion Corporation: Managers' transactions
ORION CORPORATION MANAGERS' TRANSACTIONS 11 MARCH 2025 at 09.00 EET
Orion Corporation: Managers' transactions – Liisa Hurme
Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.
Orion Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: Liisa HurmePosition: Chief Executive OfficerIssuer: Orion OyjLEI: 74370029VAHCXDR7B745Notification type: INITIAL NOTIFICATIONReference number: 99372/4/4
____________________________________________Transaction date: 2025-03-10Outside a trading venueInstrument type: SHAREISIN: FI0009014377Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE
Transaction details(1): Volume: 17000 Unit price: 0 EUR
Aggregated transactions (1): Volume: 17000 Volume weighted average price: 0 EUR
Orion Corporation
Liisa HurmePresident and CEO
Olli HuotariExecutive Vice President, Corporate Functions
Publisher:Orion CorporationCommunicationsOrionintie 1A, FI-02200 Espoo, Finlandhttp://
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2024 amounted to EUR 1,542 million and the company had about 3,700 employees at the end of the year. Orion's A and B shares are listed on Nasdaq in to access your portfolio
